🟢 Alvotech is trading 5.25% up today after Barclays upgrade

Alvotech is trading at ISK 642.00 (+5.25%) after a Barclays rating upgrade.

• Alvotech rose on September 16, 2026, after Barclays upgraded it from Underweight to Overweight and doubled its price target to $8.00 from $4.00.
• Barclays cited resubmitted biologics applications and potential FDA decisions by December 4, 2026.
• Broader biotech weakness provides a countervailing backdrop, making the upgrade the clearest catalyst.